Artemisinin [63968-64-9]

Cat# HY-B0094-200mg

Size : 200mg

Brand : MedChemExpress

Request more information

Contact local distributor :


Phone : +1 850 650 7790

Artemisinin (Qinghaosu), a sesquiterpene lactone, is an anti-malarial agent isolated from the aerial parts of Artemisia annua L. plants. Artemisinin inhibits AKT signaling pathway by decreasing pAKT in a dose-dependent manner. Artemisinin reduces cancer cell proliferation, migration, invasion, tumorigenesis and metastasis and has neuroprotective effects.

For research use only. We do not sell to patients.

Artemisinin Chemical Structure

Artemisinin Chemical Structure

CAS No. : 63968-64-9

This product is a controlled substance and not for sale in your territory.

Based on 15 publication(s) in Google Scholar

Other Forms of Artemisinin:

  • Artemisinin-d3 Get quote
  • Artemisinin-13C,d4 Get quote
  • Artemisinin (Standard) Get quote

    Artemisinin purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2019 Oct;118:109383.  [Abstract]

    ART (Artemisinin) suppresses the phosphorylation of AKT in UMRC-2 xenograft tumor. Tumors are homogenized in RIPA buffer. The protein levels were measured by western blot analysis.

    View All Parasite Isoform Specific Products:

    View All Isoforms
    Amebae Coccidia Leishmania Mite Plasmodium Toxoplasma Trypanosoma Schistosome

    View All Akt Isoform Specific Products:

    View All Isoforms
    Akt Akt1 Akt2 Akt3
    Description

    Artemisinin (Qinghaosu), a sesquiterpene lactone, is an anti-malarial agent isolated from the aerial parts of Artemisia annua L. plants[1]. Artemisinin inhibits AKT signaling pathway by decreasing pAKT in a dose-dependent manner. Artemisinin reduces cancer cell proliferation, migration, invasion, tumorigenesis and metastasis and has neuroprotective effects[2].

    IC50 & Target[2]

    Plasmodium

     

    Cellular Effect
    Cell Line Type Value Description References
    A-375 IC50
    > 50 μM
    Compound: ART
    Antiproliferative activity against human A375 cells after 72 hrs by CCK-8 assay
    Antiproliferative activity against human A375 cells after 72 hrs by CCK-8 assay
    [PMID: 29597166]
    A-375 IC50
    > 50 μM
    Compound: Artemisinin
    Cytotoxicity against human A375 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human A375 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    [PMID: 29789258]
    A-431 IC50
    39.03 μM
    Compound: Artemisinin
    Antiproliferative activity against human A431 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Antiproliferative activity against human A431 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    [PMID: 31546197]
    A549 IC50
    > 300 μM
    Compound: Artemisinin
    Antiproliferative activity against human A549 cells assessed as cell growth inhibition by MTT assay
    Antiproliferative activity against human A549 cells assessed as cell growth inhibition by MTT assay
    [PMID: 31945642]
    A549 IC50
    > 50 μM
    Compound: ART
    Antiproliferative activity against human A549 cells after 72 hrs by CCK-8 assay
    Antiproliferative activity against human A549 cells after 72 hrs by CCK-8 assay
    [PMID: 29597166]
    A549 IC50
    > 50 μM
    Compound: ART
    Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay
    [PMID: 30837097]
    A549 IC50
    > 50 μM
    Compound: Artemisinin
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    [PMID: 29789258]
    A549 IC50
    39.03 μM
    Compound: Artemisinin
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    [PMID: 31546197]
    A549 IC50
    9.85 μM
    Compound: Artemisinin
    Anticancer activity against human A549 cells assessed as cell growth inhibition measured for 72 hrs by MTT assay
    Anticancer activity against human A549 cells assessed as cell growth inhibition measured for 72 hrs by MTT assay
    [PMID: 34303874]
    ADR5000 cell line EC50
    26.9 μM
    Compound: 1
    Cytotoxicity against human CEM/ADR5000 cells over-expressing P-gp assessed as reduction in cell viability after 72 hrs by resazurin dye based assay
    Cytotoxicity against human CEM/ADR5000 cells over-expressing P-gp assessed as reduction in cell viability after 72 hrs by resazurin dye based assay
    [PMID: 29887512]
    BEAS-2B IC50
    7.53 μM
    Compound: Artemisinin
    Anticancer activity against human BEAS-2B cells assessed as cell growth inhibition measured for 72 hrs by MTT assay
    Anticancer activity against human BEAS-2B cells assessed as cell growth inhibition measured for 72 hrs by MTT assay
    [PMID: 34303874]
    BT-549 IC50
    40 μM
    Compound: Artemisinin
    Antiproliferative activity against human BT-549 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay
    Antiproliferative activity against human BT-549 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay
    [PMID: 27010926]
    CCRF-CEM EC50
    36.9 μM
    Compound: 1
    Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by resazurin dye based assay
    Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by resazurin dye based assay
    [PMID: 29887512]
    COLO 205 IC50
    39.03 μM
    Compound: Artemisinin
    Antiproliferative activity against human COLO205 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Antiproliferative activity against human COLO205 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    [PMID: 31546197]
    HCT-116 IC50
    > 50 μM
    Compound: ART
    Antiproliferative activity against human HCT116 cells after 72 hrs by CCK-8 assay
    Antiproliferative activity against human HCT116 cells after 72 hrs by CCK-8 assay
    [PMID: 29597166]
    HCT-15 IC50
    > 300 μM
    Compound: Artemisinin
    Antiproliferative activity against human HCT-15 cells assessed as cell growth inhibition by MTT assay
    Antiproliferative activity against human HCT-15 cells assessed as cell growth inhibition by MTT assay
    [PMID: 31945642]
    HEK293 IC50
    > 120 nM
    Compound: Artemisinin
    Cytotoxicity against HEK293 cells by alamar blue assay
    Cytotoxicity against HEK293 cells by alamar blue assay
    [PMID: 27212070]
    HEK293 CC50
    > 26 μM
    Compound: Artemisinin
    Cytotoxicity against human HEK293 cells assessed as cell viability measured for 24 hrs by MTT assay
    Cytotoxicity against human HEK293 cells assessed as cell viability measured for 24 hrs by MTT assay
    [PMID: 34303874]
    HepG2 CC50
    > 30 μM
    Compound: ART
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter-Glo assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter-Glo assay
    [PMID: 33620219]
    HepG2 IC50
    > 300 μM
    Compound: Artemisinin
    Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition by MTT assay
    [PMID: 31945642]
    HepG2 IC50
    > 50 μM
    Compound: ART
    Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay
    [PMID: 30837097]
    HepG2 IC50
    4.09 μM
    Compound: Artemisinin
    Anticancer activity against human HepG2 cells assessed as cell growth inhibition measured for 72 hrs by MTT assay
    Anticancer activity against human HepG2 cells assessed as cell growth inhibition measured for 72 hrs by MTT assay
    [PMID: 34303874]
    HL-60 IC50
    40 μM
    Compound: Artemisinin
    Antiproliferative activity against human HL-60 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    Antiproliferative activity against human HL-60 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    [PMID: 27010926]
    Huh-7 CC50
    > 100 μg/mL
    Compound: Artemisinin
    Cytotoxicity against human HuH7 cells after 72 hrs by MTT assay
    Cytotoxicity against human HuH7 cells after 72 hrs by MTT assay
    [PMID: 26922227]
    HUVEC IC50
    1.1 μM
    Compound: ART
    Cytotoxicity against HUVEC assessed as reduction in cell number after 48 hrs by MTT assay
    Cytotoxicity against HUVEC assessed as reduction in cell number after 48 hrs by MTT assay
    [PMID: 28549888]
    K562 IC50
    39.03 μM
    Compound: Artemisinin
    Antiproliferative activity against human K562 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Antiproliferative activity against human K562 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    [PMID: 31546197]
    L02 IC50
    > 100 μM
    Compound: ART
    Cytotoxicity against human L02 cells measured after 48 hrs by MTT assay
    Cytotoxicity against human L02 cells measured after 48 hrs by MTT assay
    [PMID: 30837097]
    L02 IC50
    > 50 μM
    Compound: ART
    Antiproliferative activity against human L02 cells after 72 hrs by CCK-8 assay
    Antiproliferative activity against human L02 cells after 72 hrs by CCK-8 assay
    [PMID: 29597166]
    L02 IC50
    > 50 μM
    Compound: Artemisinin
    Cytotoxicity against human L02 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human L02 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    [PMID: 29789258]
    L02 IC50
    0.43 μM
    Compound: 1b; ARS
    Cytotoxicity against human L02 cells assessed as cell viability after 24 hrs by MTT assay
    Cytotoxicity against human L02 cells assessed as cell viability after 24 hrs by MTT assay
    [PMID: 33636536]
    L02 IC50
    8.25 μM
    Compound: Artemisinin
    Anticancer activity against human L02 cells assessed as cell growth inhibition measured for 72 hrs by MTT assay
    Anticancer activity against human L02 cells assessed as cell growth inhibition measured for 72 hrs by MTT assay
    [PMID: 34303874]
    L6 CC50
    > 350 μM
    Compound: ART
    Cytotoxicity against rat L6 cels assessed as reduction in cell viability after 72 hrs by Alamar Blue dye-based fluorometric analysis
    Cytotoxicity against rat L6 cels assessed as reduction in cell viability after 72 hrs by Alamar Blue dye-based fluorometric analysis
    [PMID: 30615444]
    L6 IC50
    450 μM
    Compound: ART
    Cytotoxicity against rat L6 cells after 70 hrs by alamar blue staining based fluorometric assay
    Cytotoxicity against rat L6 cells after 70 hrs by alamar blue staining based fluorometric assay
    [PMID: 28279559]
    L6 IC50
    450.5 μM
    Compound: art
    Cytotoxicity against rat L6 cells after 70 hrs by Alamar blue assay
    Cytotoxicity against rat L6 cells after 70 hrs by Alamar blue assay
    [PMID: 33148495]
    L6 IC50
    450.5 μM
    Compound: ART
    Cytotoxicity in rat L6 cells assessed as reduction in cell viability incubated for 72 hrs by alamar blue assay
    Cytotoxicity in rat L6 cells assessed as reduction in cell viability incubated for 72 hrs by alamar blue assay
    [PMID: 30962114]
    L6 IC50
    450.5 μM
    Compound: ART
    Cytotoxicity against rat L6 cells assessed as reduction in cell viability after 72 hrs by Alamar blue assay
    Cytotoxicity against rat L6 cells assessed as reduction in cell viability after 72 hrs by Alamar blue assay
    [PMID: 27344215]
    MCF7 IC50
    > 50 μM
    Compound: ART
    Antiproliferative activity against human MCF7 cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells measured after 48 hrs by MTT assay
    [PMID: 30837097]
    MCF7 IC50
    > 50 μM
    Compound: Artemisinin
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    [PMID: 29789258]
    MCF7 IC50
    1.4 x 10-4 μM
    Compound: ART
    Cytotoxicity against human MCF7 cells assessed as reduction in cell number after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell number after 48 hrs by MTT assay
    [PMID: 28549888]
    MDA-MB-231 IC50
    > 100 μM
    Compound: ART
    Antiproliferative activity against human MDA-MB-231 cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells measured after 48 hrs by MTT assay
    [PMID: 30837097]
    MDA-MB-231 IC50
    > 50 μM
    Compound: Artemisinin
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    [PMID: 29789258]
    MDA-MB-231 IC50
    39.03 μM
    Compound: Artemisinin
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    [PMID: 31546197]
    MRC5 CC50
    > 25 μM
    Compound: Artemisinin
    Cytotoxicity against human MRC5 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Cytotoxicity against human MRC5 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    [PMID: 36282784]
    MRC5 IC50
    50.3 μM
    Compound: Artemisinin
    Cytotoxicity against human MRC5 cells assessed as cell growth inhibition and measured after 2 days by WST-8 assay
    Cytotoxicity against human MRC5 cells assessed as cell growth inhibition and measured after 2 days by WST-8 assay
    [PMID: 35512262]
    PC-12 IC50
    > 50 μM
    Compound: ART
    Antiproliferative activity against rat PC12 cells after 72 hrs by CCK-8 assay
    Antiproliferative activity against rat PC12 cells after 72 hrs by CCK-8 assay
    [PMID: 29597166]
    PC-3 IC50
    39.03 μM
    Compound: Artemisinin
    Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    [PMID: 31546197]
    SH-SY5Y IC50
    > 50 μM
    Compound: ART
    Antiproliferative activity against human SH-SY5Y cells after 72 hrs by CCK-8 assay
    Antiproliferative activity against human SH-SY5Y cells after 72 hrs by CCK-8 assay
    [PMID: 29597166]
    SH-SY5Y IC50
    > 50 μM
    Compound: Artemisinin
    Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability after 72 hrs by MTT assay
    [PMID: 29789258]
    SMMC-7721 IC50
    0.63 μM
    Compound: 1b; ARS
    Cytotoxicity against human SMMC-7721 cells assessed as cell viability after 24 hrs by MTT assay
    Cytotoxicity against human SMMC-7721 cells assessed as cell viability after 24 hrs by MTT assay
    [PMID: 33636536]
    U-87MG ATCC IC50
    > 50 μM
    Compound: Artemisinin
    Cytotoxicity against human U87 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human U87 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    [PMID: 29789258]
    Vero IC50
    > 16.86 μM
    Compound: Artemisinin
    Cytotoxicity against African green monkey Vero cells after 48 hrs by neutral red uptake assay
    Cytotoxicity against African green monkey Vero cells after 48 hrs by neutral red uptake assay
    [PMID: 27936446]
    In Vitro

    Artemisinin (Qinghaosu) (25 or 50 μM; 24 hours) concentration-dependently suppresses Aβ25-35 induced cytotoxicity in PC12 cells[1].
    Artemisinin (1-100 μM; 24 hours) selectively inhibits cancer cell growth in a dose-dependent manner with IC50 values of 31.30 ± 0.73 μM in UMRC-2 cells and 23.97 ± 0.92 CAKI-2 cells[2].
    Artemisinin (25, 50 μM; 24 hours) suppresses the phosphorylation of AKT in UMRC-2 and CAKI-2 cells in a dose-dependent manner[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Cell Cytotoxicity Assay[1]

    Cell Line: PC12 cells
    Concentration: 25 or 50 μM
    Incubation Time: 24 hours
    Result: Protected and rescue PC12 cells against Aβ25-35-induced cell death.

    Cell Viability Assay[2]

    Cell Line: RCC cells, RCC cell lines UMRC-2 and CAKI-2, and normal renal cell HK-2
    Concentration: 1, 5, 10, 50, and 100 μM
    Incubation Time: 24 hours
    Result: Selectively inhibited cancer cell growth in a dose-dependent manner.

    Western Blot Analysis[2]

    Cell Line: UMRC-2 and CAKI-2 cells
    Concentration: 25, 50 μM
    Incubation Time: 24 hours
    Result: Decreased pAKT in a dose-dependent manner.
    In Vivo

    Artemisinin (gavage; 20 mg/kg/day; for two weeks) suppresses UMRC-2 xenograft tumor growth[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: 4-6 weeks old male nude mice[2]
    Dosage: 20 mg/kg
    Administration: gavage; every day for two weeks
    Result: Suppressed UMRC-2 xenograft tumor growth.
    Clinical Trial
    Molecular Weight

    282.33

    Formula

    C15H22O5

    CAS No.

    63968-64-9

    Appearance

    Solid

    Color

    White to off-white

    SMILES

    O=C1[C@H](C)[C@]2(02)CC[C@@H](C)[C@]3(02)CC[C@@](O4)(C)OO[C@]32[C@]4(02)O1

    Structure Classification
    • Terpenoids
    • Sesquiterpenes
    Initial Source
    • Plants
    • Leguminosae
    • Piscidia erythrina L.
    • Plants
    • Compositae
    Shipping

    Room temperature in continental US; may vary elsewhere.

    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 1 year
    -20°C 6 months
    Solvent & Solubility
    In Vitro: 

    DMSO : 50 mg/mL (177.10 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    H2O : < 0.1 mg/mL (insoluble)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 3.5420 mL 17.7098 mL 35.4195 mL
    5 mM 0.7084 mL 3.5420 mL 7.0839 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.08 mg/mL (7.37 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.08 mg/mL (7.37 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: ≥98.0%

    References
    • [1]. Zeng Z, et al. Artemisinin protects PC12 cells against β-amyloid-induced apoptosis through activation of the ERK1/2 signaling pathway. Redox Biol. 2017 Apr 4;12:625-633.  [Content Brief]

      [2]. Lin SP, et al. Artemisinin Prevents Glutamate-Induced Neuronal Cell Death Via Akt Pathway Activation. Front Cell Neurosci. 2018 Apr 20;12:108.  [Content Brief]

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 3.5420 mL 17.7098 mL 35.4195 mL 88.5489 mL
    5 mM 0.7084 mL 3.5420 mL 7.0839 mL 17.7098 mL
    10 mM 0.3542 mL 1.7710 mL 3.5420 mL 8.8549 mL
    15 mM 0.2361 mL 1.1807 mL 2.3613 mL 5.9033 mL
    20 mM 0.1771 mL 0.8855 mL 1.7710 mL 4.4274 mL
    25 mM 0.1417 mL 0.7084 mL 1.4168 mL 3.5420 mL
    30 mM 0.1181 mL 0.5903 mL 1.1807 mL 2.9516 mL
    40 mM 0.0885 mL 0.4427 mL 0.8855 mL 2.2137 mL
    50 mM 0.0708 mL 0.3542 mL 0.7084 mL 1.7710 mL
    60 mM 0.0590 mL 0.2952 mL 0.5903 mL 1.4758 mL
    80 mM 0.0443 mL 0.2214 mL 0.4427 mL 1.1069 mL
    100 mM 0.0354 mL 0.1771 mL 0.3542 mL 0.8855 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Artemisinin Related Classifications

    Help & FAQs

    Keywords:

    Artemisinin63968-64-9Qinghaosu NSC 369397NSC369397NSC 369397NSC-369397HCVParasiteAktFerroptosisHepatitis C virusPKBProtein kinase BInhibitorinhibitorinhibit

    You might also be interested by the following products:



    Cat#
    Description
    Cond.
    Price Bef. VAT
    AB0205-100g
     100g 
    HY-111391-5g
     5g 
    HY-N0176-100mg
     100mg